The target INR range for patients on warfarin therapy varies depending on their condition but is typically between 2.0 and 3.0.

Frequency of testing depends on individual patient needs, but initially, it may be done weekly or bi-weekly until stable, then less frequently thereafter.

Yes, the PT / INR Test can help diagnose various clotting disorders, including those related to liver disease or genetic clotting factor deficiencies.

Medications, dietary changes, liver function, and underlying health conditions can all influence PT / INR results.

Yes, the PT / INR Test is a safe and standard diagnostic procedure used worldwide to monitor blood clotting ability and adjust anticoagulant therapy.

Elevated S.G.P.T levels may suggest liver damage or disease, such as hepatitis or fatty liver.

Yes, certain medications and supplements can influence S.G.P.T levels. It’s essential to inform your healthcare provider about all medications you are taking.

No, fasting is generally not required for this test unless specified by your healthcare provider.

The frequency of testing depends on your health condition and your healthcare provider’s recommendations.

Abnormal levels may indicate underlying liver issues. Further evaluation and treatment may be necessary based on your test results.

Lumpectomy preserves more of the breast tissue, while mastectomy involves removing the entire breast. Both have similar long-term survival rates for early-stage breast cancer.